Patrick J. McEnany
Co-Founder, Chairman, President and Chief Executive Officer
Patrick J. McEnany has been Chief Executive Officer and a director of Catalyst since its formation in January 2002. In 2006 he became Chairman, President and Chief Executive Officer. From 1991 to April of 1997, Mr. McEnany was Chairman and Chief Executive Officer of Royce Laboratories, Inc. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served as President of the wholly-owned Royce Laboratories subsidiary and Vice President of Corporate Development for Watson Pharmaceuticals, Inc. From 1993 through 1997, he also served as Vice Chairman and Director of the National Association of Pharmaceutical Manufacturers. He currently serves on the Board of Directors for the Jackson Memorial Hospital Foundation.
Philip H. Coelho
Philip H. Coelho, Co-Founder and Chief Technology Officer of SynGen, Inc., is an engineer and inventor, educated at the University of California, Davis, where he specialized in thermodynamics and machine design. He has been awarded more than 30 U.S. patents related to cell cryopreservation, cryogenic robotics, cell selection, blood protein harvesting, and surgical hemostasis. During his tenure as Founder, Chairman and CEO of ThermoGenesis Corp. (n/k/a CESCA Therapeutics, Inc.), Mr. Coelho developed the BioArchive robotic system for controlled-rate freezing and cryogenically archiving units of hematopoietic stem and progenitor cells (HSPCs), derived from placental/cord blood, and the AutoXpress System, which automates the sterile harvesting of HSPCs from cord blood into a 25-mL dual-compartment freezing bag. The BioArchive and AutoXpress Systems have defined Good Manufacturing Practice standards in cord blood processing and banking worldwide. As CTO of SynGen, Inc., Mr. Coelho is leading the development of new techniques for the clinical and research fields that improve the speed and efficiency of harvesting target cell populations resident within peripheral or placental/cord blood or bone marrow and washing/purifying ex-vivo expanded cell populations derived from those cells. Mr. Coelho has been a member of the Catalyst Board of Directors since October 2002.
Richard J. Daly joined our Board of Directors in February 2015. He currently serves as the Chairman and CEO of Neuralstem, Inc., an emerging biotechnology company with clinical programs in CNS disorders. Until October 2014, Mr. Daly served as President of AstraZeneca US Diabetes, where he led all commercial and medical plans and objectives for a $1.2 billion, 3,000-employee division, including the successful launch of an orphan/rare disorder drug, Myalept, for lipodystrophy. From 2011 through 2013, Mr. Daly served as a Co-Founder of, and an investor in, Sagepath Partners, a company providing the pharmaceutical industry with outsourced commercial services. From 2008 to 2011, Mr. Daly was employed by Takeda N.A., the North American subsidiary of Takeda Pharmaceuticals, serving first as Vice President, Integration, leading a 6,500-person commercial/R&D merger between TAP Pharmaceuticals and Takeda N.A., then as Executive Vice President of Takeda N.A., with commercial responsibility for all businesses in the Americas. From 2006 to 2008, Mr. Daly served as the Vice President, Commercial Strategy for TAP Pharmaceuticals, a joint venture between Takeda Pharmaceuticals and Abbott Labs. In 1998, Mr. Daly was a founding member of the leadership team of Takeda Pharmaceuticals N.A., serving initially as the Senior Director of Marketing. Between 1998 and 2006, Mr. Daly took on roles of increasing responsibility culminating in his appointment as Senior Vice President, Marketing (2001-2006). Mr. Daly received his bachelor of science degree in microbiology from the University of Notre Dame in 1983 and his MBA from the Kellogg School of Management, Northwestern University in 1998.
Donald A. Denkhaus
Donald A. Denkhaus joined our Board of Directors in February 2015 and currently chairs the Audit Committee of our board. Since 2005, Mr. Denkhaus has been Chairman and Chief Financial Officer of The Kitchen, LLC, a company providing language dubbing and subtitling services to the television industry. From 1970 through 2002, Mr. Denkhaus, who is licensed as a certified public accountant, worked for Arthur Andersen LLP, a global professional services organization, where he was an audit partner for twenty-two years and held numerous leadership positions, including as head of Andersen’s South Florida audit practice and, from 1998 through 2002, as Audit Practice Partner responsible for Andersen’s offices in Florida and Puerto Rico. From 2010 to 2013, Mr. Denkhaus was Chair of Nuovo Biologics, a privately held biotech company currently seeking FDA approval of an antiviral drug, and, from 2004 until its sale in 2009, Mr. Denkhaus served on the Board of Directors and as chair of the audit committee of Noven Pharmaceuticals, a publicly traded specialty pharmaceutical company focused on women’s health and psychiatry. Mr. Denkhaus received an MBA with a major in finance from the University of Maryland and a bachelor’s degree in business administration with a major in accounting from Kent State University.
Charles B. O’Keeffe
Lead Independent Director
Charles B. O’Keeffe is Professor, Pharmacology, and Epidemiology & Community Health, at the Virginia Commonwealth University School of Medicine (VCU). Mr. O’Keeffe joined VCU after retiring as President and CEO of Reckitt Benckiser Pharmaceuticals, Inc. Mr. O’Keeffe has led a distinguished career in the pharmaceutical industry and government. He served as President of Pharmaceutical Services Inc., and President of Washington Reference Laboratories. He has served in the White House for three presidents—as advisor, special assistant for international health and deputy director for international affairs in the Office of Drug Abuse Policy—and has served on US delegations to the World Health Assembly and the UN Commission on Narcotic Drugs.
David S. Tierney
David S. Tierney, MD, currently serves as CEO of Icon Biosciences Inc., a privately held ophthalmic drug delivery company. Previously, Dr. Tierney served as President and Chief Operating Officer (and a member of the Board of Directors) of Oceana Therapeutics, Inc., a private specialty pharmaceutical company, from the organization of the company in 2008 until the sale of the company to Salix Pharmaceuticals, Ltd., in December 2011. Dr. Tierney also served as Chief Executive Officer and a director of Valera Pharmaceuticals, Inc., until it was acquired by Indevus Pharmaceuticals, Inc., in April 2007. From January 2000 to August 2000, Dr. Tierney served as President of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company, where he had responsibility for all of Biovail’s research and development and regulatory and clinical activities. From March 1997 to January 2000, Dr. Tierney was Senior Vice President of Drug Development at Roberts Pharmaceutical Corporation, with responsibility for all research and development activities, and overall responsibility for drug development, medical affairs, world¬wide regulatory affairs and chemical process development, as well as being part of the executive management team. From December 1989 to March 1997, Dr. Tierney was at Élan Corporation in a variety of management positions. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland, and subsequently trained in internal medicine. Dr. Tierney also serves on the Board of Directors of Kempharm, Inc.